Mobile Clinic Services for Women Who Inject Drugs

Overseen By Lauren Violette, MPH

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Washington

Must be taking: PrEP, MOUD

Disqualifiers: HIV, Psychological comorbidities, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 3

50 Participants Needed

Trial Summary

What is the purpose of this trial?

The investigators will implement a non-randomized observational clinical trial that will include a pop-up clinic for women who inject drugs (WWID) near venues for exchange sex and drug use in north Seattle. The pop-up clinic will be housed within a van and serve as a research extension of the SHE Clinic, a Harborview Medical Center run clinic for women who exchange sex and use drugs in north Seattle. Through the implementation of the pop-up clinic, the investigators will aim to assess: 1. The impact of the pop-up clinic on uptake and sustained use of HIV pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD) among WWID. 2. The impact of point of care (POC) sexually transmitted infection (STI) testing on STI treatment completion rates. 3. The acceptability and feasibility of providing HIV prevention care for WWID and exchange sex in a pop-up van clinic.

Research Team

Maria Corcorran, MD, MPH

Principal Investigator

University of Washington

Eligibility Criteria

This trial is for women over 18 who inject drugs and are not known to have HIV. Participants must be willing to give informed consent, identify as female, and have a history of drug injection.

Inclusion Criteria

Ever injected drugs

I identify as female.

Willing and able to provide informed consent to participate in the study

Exclusion Criteria

Living with HIV

Never injected drugs

I am under 18 years old.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Enrollment and Initial Assessment

Participants provide consent, undergo eligibility assessment for PrEP and MOUD, and receive initial clinical care and testing

1 week

1 visit (in-person)

Treatment and Monitoring

Participants receive PrEP and MOUD, undergo POC STI testing, and participate in adherence monitoring and surveys

6 months

Monthly visits (in-person)

Follow-up

Participants are monitored for sustained use of PrEP and MOUD, and receive results and treatment as necessary

6 months

2 visits (in-person) at 3 and 6 months

Treatment Details

Interventions

• Mobile Van Clinic

Trial Overview The study tests the effectiveness of a mobile van clinic in increasing the use of HIV prevention medication (PrEP) and treatments for opioid addiction among women who inject drugs. It also evaluates on-site STI testing's impact on treatment completion rates.

Participant Groups

Group I: Study cohort Experimental Treatment 1 Intervention

The investigators will enroll 50 female-identifying people who present to the clinical van for care and follow them for 6 months. The investigators will assess uptake of PrEP and buprenorphine; POC STI testing and treatment completion rates; sustained use of PrEP and buprenorphine at months 3 and 6 (n=50). The investigators will conduct surveys to assess and characterize the acceptability and feasibility of venue-based primary and HIV prevention care among women who inject drugs (WWID).

Who Is Running the Clinical Trial?

University of Washington

Lead Sponsor

Trials

1,858

Recruited

2,023,000+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials

2,658

Recruited

3,409,000+